These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 1350350)
21. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. Paul ML; Graybiel AM; David JC; Robertson HA J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113 [TBL] [Abstract][Full Text] [Related]
22. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity. LaHoste GJ; Yu J; Marshall JF Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797 [TBL] [Abstract][Full Text] [Related]
23. Pressure reversed extracellular striatal dopamine decrease produced by D1 receptor agonist SKF 38393, and D2 receptor agonist LY 171555, but failed to change the effect of the activation of both D1 and D2 receptors. Abraini JH; Fechtali T; Rostain JC Neuroscience; 1992 Sep; 50(2):395-402. PubMed ID: 1359460 [TBL] [Abstract][Full Text] [Related]
24. The D2 agonist quinpirole potentiates the discriminative stimulus effects of the D1 agonist SKF 38393. Williams JE; Woolverton WL Pharmacol Biochem Behav; 1990 Oct; 37(2):289-93. PubMed ID: 1981936 [TBL] [Abstract][Full Text] [Related]
25. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Arnt J; Bøgesø KP; Hyttel J; Meier E Pharmacol Toxicol; 1988 Mar; 62(3):121-30. PubMed ID: 3259694 [TBL] [Abstract][Full Text] [Related]
26. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors. Subramaniam S; Lucki I; McGonigle P Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781 [TBL] [Abstract][Full Text] [Related]
27. Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia. Lublin H; Gerlach J; Peacock L Clin Neuropharmacol; 1992 Dec; 15(6):448-58. PubMed ID: 1362136 [TBL] [Abstract][Full Text] [Related]
28. Endogenous dopaminergic tone and dopamine agonist action. Treseder SA; Smith LA; Jenner P Mov Disord; 2000 Sep; 15(5):804-12. PubMed ID: 11009183 [TBL] [Abstract][Full Text] [Related]
29. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies. Hu XT; White FJ Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772 [TBL] [Abstract][Full Text] [Related]
30. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Walters JR; Bergstrom DA; Carlson JH; Chase TN; Braun AR Science; 1987 May; 236(4802):719-22. PubMed ID: 2953072 [TBL] [Abstract][Full Text] [Related]
31. The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum. Delfs JM; Kelley AE Neuroscience; 1990; 39(1):59-67. PubMed ID: 1982467 [TBL] [Abstract][Full Text] [Related]
32. Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioral responses: a quantitative phenomenological study in rats. Longoni R; Spina L; Di Chiara G Life Sci; 1987 Nov; 41(18):2135-45. PubMed ID: 2959833 [TBL] [Abstract][Full Text] [Related]
33. Dopamine depletion preferentially impairs D1- over D2-receptor regulation of striatal in vivo acetylcholine release. Bertorelli R; Zambelli M; Di Chiara G; Consolo S J Neurochem; 1992 Jul; 59(1):353-7. PubMed ID: 1351928 [TBL] [Abstract][Full Text] [Related]
34. Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists. Hubbard CA; Trugman JM Mov Disord; 1993 Oct; 8(4):473-8. PubMed ID: 7901761 [TBL] [Abstract][Full Text] [Related]
35. Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants. Serra G; Collu M; D'Aquila PS; De Montis GM; Gessa GL Brain Res; 1990 Sep; 527(2):234-43. PubMed ID: 1979237 [TBL] [Abstract][Full Text] [Related]
36. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767 [TBL] [Abstract][Full Text] [Related]
37. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists. Giorgi O; Biggio G Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234 [TBL] [Abstract][Full Text] [Related]
38. Dopaminergic modulation of cholinergic responses in rat medial prefrontal cortex: an electrophysiological study. Yang CR; Mogenson GJ Brain Res; 1990 Aug; 524(2):271-81. PubMed ID: 1981327 [TBL] [Abstract][Full Text] [Related]
39. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion. Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981 [TBL] [Abstract][Full Text] [Related]
40. Kappa opioid mediated locomotor activity in the preweanling rat: role of pre- and postsynaptic dopamine receptors. McDougall SA; Garmsen GM; Meier TL; Crawford CA Psychopharmacology (Berl); 1997 Sep; 133(1):62-8. PubMed ID: 9335082 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]